You are here: Home > Love Lab

Genes and Signals Regulating Mammalian Hematopoiesis

• Paul E. Love, MD, PhD, Head, Section on Hematopoiesis and Lymphocyte Biology
• Guillaume Gaud, PhD, Research Fellow
• LiQi Li, MD, PhD, Staff Scientist
• Teri Hatzihristidis, PhD, Visiting Fellow
• Bin Zhao, PhD, Visiting Fellow
• Dalal El-Khoury, BS, Technician
• Jan Lee, BS, Technician
• Lauren Clubb, BS, Postbaccalaureate Intramural Research Training Award Fellow
• Seeyoung Choi, PhD, Contract employee

Our research focuses on the development of the mammalian hematopoietic system. A long-term area of interest for our laboratory is the study of signal transduction molecules and pathways that regulate T lymphocyte maturation in the thymus. Currently, we are analyzing transgenic and conditional non-signaling mutants of T cell antigen receptor (TCR) signaling subunits, made in our lab, to evaluate the importance of individual TCR signaling chains and motifs at specific stages of T cell development and in mature T cells. We are also investigating whether modification of TCR signaling subunits can be used to enhance the tumoricidal activity of T cells. Using gene profiling, we are seeking to identify proteins that are important for fine-tuning the T cell–signaling response in developing and mature T lymphocytes. In conjunction with checkpoint inhibitors for immunotherapy in humans, such molecules may also be targets to enhance anti-tumor activity. We are also investigating the function of new T cell–specific proteins that we identified by subtraction library screening. Our studies revealed a critical role for one of these proteins, called Themis, in T cell development by enhancing the TCR–signaling response in thymocytes. We found that another newly identified protein, Fbxl12, is important for regulating proliferation during early T cell development. Another area of investigation focuses on hematopoietic stem cells (HSCs) and early stages of T cell, B cell, and erythrocyte development. We initiated characterization of a protein (Ldb1) that is important for the generation and maintenance/self-renewal of HSCs, which revealed a critical function for Ldb1 as a key subunit of multimeric DNA–binding complexes in controlling the self-renewal/differentiation cell-fate decision in HSCs. Current work, which involves genome-wide screening by RNA-seq and ChIP-seq, seeks to extend our knowledge of the role of Ldb1 complexes in regulating gene transcription and to explore the function of such complexes in other hematopoietic lineages. For example, we have begun to investigate the importance of Ldb1 complexes for regulating self-renewal in immature thymocytes and in the induction of T cell acute lymphoblastic leukemia (T-ALL). Our results suggest that Ldb1 complexes represent potential therapeutic targets for the treatment of an aggressive form of childhood leukemia called early T progenitor T cell acute lymphoblastic leukemia (ETP-T-ALL).

T cell antigen receptor signaling in thymocyte development

Much of our research has focused on the role of TCR signal transduction in thymocyte development. Signal transduction sequences, termed immuno-receptor tyrosine-based activation motifs (ITAMs), are contained within four distinct subunits of the multimeric TCR complex (CD3-zeta, CD3-gamma, CD3-delta, and CD3-epsilon). Di-tyrosine residues within ITAMs are phosphorylated upon TCR engagement; their function is to recruit signaling molecules, such as protein tyrosine kinases, to the TCR complex, thereby initiating the T cell–activation cascade. Though conserved, ITAM sequences are nonidentical, raising the possibility that the diverse developmental and functional responses controlled by the TCR may be partly regulated by distinct ITAMs through the recruitment of different effector molecules. We previously generated CD3-zeta–deficient and CD3-epsilon–deficient mice by gene targeting. We genetically reconstituted the mice with transgenes encoding wild-type or signaling-deficient (ITAM–mutant) forms of CD3-zeta and CD3-epsilon and characterized the developmental and functional consequences of the alterations for TCR signaling. We found that TCR–ITAMs are functionally equivalent but act in concert to amplify TCR signals and that TCR signal amplification is critical for thymocyte selection, the process by which potentially useful immature T cells are instructed to survive and differentiate further (positive selection) and by which potentially autoreactive cells, which may cause autoimmune disease, are deleted in the thymus (negative selection).

We also found that a complete complement of TCR–ITAMs is not required for most mature T cell effector functions. However, recent work demonstrated a requirement for ITAM multiplicity for the generation of T follicular helper cells, which are necessary for optimal B cell antibody responses. One possible explanation for the relatively mild phenotype observed in the TCR ITAM–reduced mice is that ITAM–mediated signal amplification is not required for most mature T cell activation responses; another is that, in ITAM–mutant mice, T cells exhibit normal functional responsiveness because of compensatory mechanisms (such as regulated expression of other signaling molecules) imposed during development. To resolve this question, we recently generated a TCR–zeta chain conditional knock-in mouse in which T cell development and selection can occur without attenuation of TCR signaling (i.e., in the presence of a wild-type 3-ITAM “6Y” zeta chain), but in which mature, post-selection T cells may be induced to express TCRs containing signaling-defective (0-ITAM “6F”) zeta chains in lieu of wild-type zeta chains (Figure 1). Thus, mature T cell signaling should not be influenced by potential compensatory mechanisms that operate during T cell maturation, and T cells in such mice should be faithful indicators of the role of multiple TCR ITAMs in mediating specific, mature T cell responses. Preliminary experiments confirmed that the knock-in zeta locus functions as predicted. We are currently evaluating the effect of late ‘switching’ from 6Y zeta to 6F zeta in mature T cells generated with wild-type 6Y zeta containing TCRs. The experimental conditions will more closely mimic those in which TCR signaling is attenuated pharmacologically to treat human diseases such as autoimmunity. In addition, the experiments should provide information relevant to the design of engineered tumor antigen–specific TCRs and chimeric antigen receptor T cells (CAR T cells), which currently are configured to express zeta ITAM signaling module(s).

Identification and characterization of proteins important for TCR fine tuning and TCR signaling

We extended our analysis of TCR–signaling subunits to other molecules that participate in or influence the TCR–signaling response. The cell-surface protein CD5 negatively regulates TCR signaling and functions in thymocyte selection. Examination of CD5 expression during T cell development revealed that surface levels of CD5 are regulated by TCR signal intensity and by the affinity of the TCR for self-peptide ligands in the thymus that mediate selection. To determine whether the ability to regulate CD5 expression is important for thymocyte selection, we generated transgenic mice that constitutively express high levels of CD5 throughout development. Over-expression of CD5 significantly impaired positive selection of some thymocytes (those that would normally express low levels of CD5) but not of others (those that would normally express high levels of CD5). The findings support a role for CD5 in modulating TCR signal transduction and thereby influencing the outcome of thymocyte selection. Current studies center on identifying the mechanism by which CD5 inhibits TCR signaling and on determining whether the protein's regulated expression during development is important for preventing autoimmunity. For that purpose, we generated a conditional CD5 deletion mouse in which CD5 expression can be removed before, during, or after T cell development. The ability of individual thymocytes to regulate CD5 expression represents a mechanism for ‘fine tuning’ the TCR–signaling response during development so that the integrated signaling response can be adjusted to permit T cell functional competency without causing autoimmunity. Reasoning that, in addition to CD5, other molecules participate in TCR tuning, we initiated microarray-based screening for genes differentially expressed in developing T cells under conditions of high- or low-affinity TCR interactions. We identified several genes from this screen for further study and are validating their function as tuning molecules. Given that the molecules regulate TCR signaling, they represent potential autoimmune-disease susceptibility markers and potential targets for treatment of patients with cancer or autoimmune disease, similar to current ‘checkpoint inhibitor’ therapies that are based on blocking the function of the induced inhibitory molecules PD-1 and CTLA-4.

Identification and characterization of Themis, a novel protein required for T cell development

Using a subtractive cDNA library–screening approach, we identified Themis, now known as Themis1, a novel T cell–specific adapter protein (Figure 2). To investigate the function of Themis1 in T cell signaling and development, we generated Themis1 knock-down cell lines, Themis1 knock-out mice (conventional and conditional), and Themis1 transgenic mice. Analysis of the effects of modulating Themis1 expression revealed a critical role for the protein in late T cell development. We obtained the following results. First, the Themis1 paralog Themis2, which is expressed in B cells, can substitute for Themis1 in T cell development. We found that the ability of the B cell–specific family Themis member Themis2 was equivalent to that of Themis1 to restore normal T cell development in Themis1^–/– mice, thus demonstrating functional redundancy of Themis1 and Themis2. Second, we generated retroviruses encoding domain-deletion mutants of Themis1, infected Themis1^–/– bone marrow progenitors, and made bone marrow chimeras to determine which regions of Themis1 are important for in vivo function. We found that the Themis1 proline-rich sequence (PRS), which mediates binding to the signaling protein Grb2, was required for in vivo function, as assessed by rescue of the developmental block in Themis1^–/– thymocytes, but that the CABIT (cysteine-containing, all beta in Themis)–domain cysteines are not essential. Third, we generated Themis2^–/– mice and began a collaboration with Richard Cornall to characterize the mice. Our results identified an important role for Themis2 in facilitating B cell activation by low-avidity, but not high-avidity, B cell receptor (BCR)–antigen interactions. Themis2 was required to elicit normal Ca²⁺ signaling via the Erk pathway in response to low-avidity interactions and was necessary for positive selection of B1 cells and germinal-center B cells by self and foreign antigens. We detected Themis2 in complexes with the signaling proteins Grb2, Lyn, and PLCgamma2 and found that Themis2 is required for normal tyrosine phosphorylation of Lyn and PLCgamma2. This subtle but clear phenotype of Themis2^–/– mice was not detected in a previous and less extensive study of Themis2^–/–, which concluded that loss of Themis2 has no effect on B cell development or function.

Our findings show that the impact of loss of Themis1 and Themis2 on T and B cell development, respectively, is strikingly similar. In each case, the main effect is on positive selection, which is controlled by low-avidity antigen-receptor interactions. This, together with the ability of Themis2 to rescue T cell development in Themis1^–/– mice, indicates that Themis1 and Themis2 perform similar functions in T and B cells.

In the past few years, we focused on determining the molecular function of Themis1. Themis1, Themis2, and a large family of related metazoan proteins contain a novel globular domain of unknown function called the CABIT module (see above and Figure 2). Using cell transfection, biochemical, and protein assay techniques, we determined that CABIT modules bind to the catalytic domain of SHP-1, a key hematopoietic protein tyrosine phosphatase. In the presence of reactive oxygen species (ROS), which are generated in activated T cells, Themis1, via its CABIT module, promoted oxidation of the SHP-1 catalytic cysteine and therefore inactivated SHP-1. The CABIT modules from all five mammalian Themis-family proteins also inhibited SHP-1, indicating that this activity was common to the CABIT module. Given that SHP-1 is an inhibitory phosphatase that functions to dampen TCR signaling by de-phosphorylating several targets, including protein tyrosine kinases, the finding established an activating function for Themis1 in cell signaling through its ability to bind to and inhibit SHP-1. Interestingly, Themis1 is highly expressed in developing thymocytes at the stage at which they undergo positive selection. It had been known for years that thymocytes are more sensitive to TCR stimulation than are mature T cells, but the reason for this sensitivity was unknown. The function of Themis1, together with its high expression in thymocytes, provides an explanation for the sensitivity of thymocytes to TCR signaling. By showing that deletion of the gene encoding SHP-1 rescues T cell development in Themis1^–/– mice, we confirmed that the primary role of Themis1 is to inhibit SHP-1. In addition to identifying the function of CABIT modules, our results provide insight into the role of other metazoan CABIT–containing proteins (which number in the hundreds). Our ongoing studies are focusing on further characterization of CABIT proteins and determining their role in development and their possible involvement in human disease.

Role of the F-box protein Fbxl12 in thymocyte development

A major aspect of the T cell maturation process is the precise regulation of cell proliferation. Rather than being a shared property among all or most developing thymocytes, proliferation is strictly limited to two stages during early development. The initial proliferative phase is driven by thymus-expressed cytokines, the second coincides with ‘beta selection’ (i.e., is initiated in cells that have productively rearranged the TCRbeta chain and express a signaling complex called the pre–TCR). The proliferative burst that accompanies beta selection is estimated to result in a 100–200 fold expansion and is essential for further differentiation and for maximizing TCR diversity. Previous work showed that beta selection–associated proliferation requires concurrent signals by the pre–TCR and the Notch receptor, but how these signals induce cell-cycle progression and why they need to be coordinated has remained unclear. Initiation of proliferation in beta-selected thymocytes requires the ubiquitin-mediated degradation of the cyclin-dependent kinase inhibitor Cdkn1b, which acts to prevent cell-cycle progression. In a recent study, we examined the molecular control of beta selection–associated proliferation. We confirmed prior findings that Cdkn1b degradation is induced by an SCF E3 ubiquitin ligase that contains the ligand-recognition subunit Fbxl1. Deletion of Fbxl1 partially blocked beta selection–associated proliferation, a defect that was rescued by co-deletion of Cdkn1b. We identified a new F-box protein, Fbxl12, that is highly expressed in thymocytes. We found that Fbxl12 also functions as an SCF E3 ligase subunit, which, like Fbxl1, directs Cdkn1b degradation. The phenotype of Fbxl12–deficient mice generated in our lab was strikingly similar to Fbxl1–deficient mice, and deletion of both Fbxl1 and Fbxl12 resulted in a severe block in beta selection–associated proliferation, indicating that Fbxl1 and Fbxl12 act in concert to regulate thymocyte proliferation. Interestingly, we found that Fbxl1 expression is induced by Notch signaling, whereas Fbxl12 expression is induced by pre-TCR signaling. Both Fbxl1 and Fbxl12 are required for thymocyte proliferation; thus, their selective regulation by Notch and the pre-TCR, respectively, provides an explanation for why concurrent Notch and pre-TCR signaling are necessary for cell-cycle progression and proliferation at the beta selection checkpoint.

Role of Ldb1 transcription complexes in hematopoiesis and in T cell acute lymphoblastic leukemia

Lim domain binding protein-1 (Ldb1) is a ubiquitously expressed nuclear protein that contains a LIM–zinc finger protein–interaction motif and a dimerization domain. In hematopoietic cells, Ldb1 functions by interacting with and/or recruiting specific partners (including the LIM–only protein Lmo2 and the transcription factors Lyl1 or Tal1 and Gata1 or Gata2) to form multi-molecular transcription complexes (Figure 3). Within the hematopoietic lineage, expression of Ldb1 is highest in progenitor cells, which include hematopoietic stem cells (HSCs). Ldb1–null (Ldb1^–/–) mice die between day 9 and 10 of gestation, preventing us from directly studying the impact of loss of Ldb1 on fetal or adult hematopoiesis. We investigated the role of Ldb1 in hematopoiesis by following the fate of Ldb1^–/– embryonic stem cells (ESCs) in mouse blastocyst chimeras and by conditional, stage-specific deletion of Ldb1. Significantly, Ldb1^–/– ESCs were capable of generating HSCs, which could give rise to both myeloid and lymphoid lineage cells; however, the number of Ldb1^–/– HSCs gradually diminished at later stages of development. Following adoptive transfer of fetal liver hematopoietic progenitor cells, Ldb1^–/– HSCs were rapidly lost, indicating a failure of self renewal or survival. More recent data indicate that the loss of Ldb1^–/– HSCs results from differentiation rather than cell death. Although expressed in ESCs, Ldb1 is not required for ESC maintenance, indicating a selective requirement in adult stem-cell populations. We performed a genome-wide screen for Ldb1–binding sites using ChIP-seq. Analysis of the ChIP-seq data revealed that Ldb1 complexes bind at the promoter or at regulatory sequences near a large number of genes known to be required for HSC maintenance. The data suggest that Ldb1 complexes function in a manner similar to Oct4/nanog/Sox2, transcription factors that are all essential in maintaining the pluripotent ESC phenotype, to regulate a core transcriptional network required for adult stem cell maintenance. Examination of the function of Ldb1 in cell lineages downstream of the HSC identified an essential function in the erythroid lineage but not in myeloid cells or lymphoid cells. Interestingly, ChIP-seq analysis of Ldb1 DNA–binding complexes demonstrated that, in HSCs, Ldb1 complexes contain the transcription factor Gata2, whereas, in erythroid progenitors, Ldb1 complexes contain Gata1 (which is highly expressed in the erythroid lineage). The results indicate that multimeric Ldb1 transcription complexes have distinct functions in the hematopoietic system depending on their subunit composition, with Gata2–containing complexes regulating expression of HSC–maintenance genes and Gata1 complexes regulating expression of erythroid-specific genes (Figure 3). Current studies aim to determine how Ldb1 complexes regulate gene expression and the role of Ldb1 dimerization in mediating long-range promoter-enhancer interactions in hematopoietic cells. In addition, we are investigating a potential role for Ldb1 in regulating self renewal of T cell progenitors in the thymus.

Acute lymphoblastic leukemias are the most common type of cancer in children. T cell acute lymphoblastic leukemia (T-ALL) results from oncogenic transformation of immature T cell progenitors (thymocytes). Mouse models of T-ALL have been generated, and one of the most informative is the Lmo2–transgenic (Lmo2-tg) mouse, which expresses high levels of the nuclear adapter Lmo2 in thymocytes. The model closely mimics a prevalent type of human T-ALL, which is associated with chromosomal mutations that result in increased expression of LMO2. We recently reported that overexpression of Lmo2 in mouse thymocytes induces T-ALL at two distinct stages of development (an early ‘ETP’ stage and a later ‘DN3’ stage). Notably, human T-ALLs can also occur at two similar stages of thymocyte maturation. The most immature forms of T-ALL in Lmo2-tg mice and in humans express high levels of the transcription factor Hhex and are designated early T progenitor (ETP) T-ALL, whereas later-stage tumors are low in Hhex but express high levels of more mature markers of T cell development, including Notch1, Dtx1, Ptcra, and Hes1. Lmo2 functions as a subunit of the multimeric Ldb1–nucleated DNA–binding complexes described above. We found that normal ETP thymocyte progenitor cells express the same Ldb1 complex subunits that are present in HSCs and that ETPs exhibit HSC characteristics, including the self-renewal potential. ETPs in Lmo2-tg mice appear to be ‘locked’ into a pattern of perpetual self renewal and are refractory to normal inductive signals that promote further differentiation. Hhex is a target of Ldb1 complexes in HSCs and ETPs, a result that strongly suggests that Ldb1 complexes are responsible for the aberrant self renewal in Lmo2-tg mice that predisposes to oncogenesis. We hypothesized that Ldb1 complexes regulate self renewal in ETPs as well as in HSCs. Lmo2 is normally down-regulated when thymocytes undergo T lineage commitment, suggesting that extinguishing expression of Lmo2 (and by extension, Ldb1 complexes) is important for T cell differentiation and that failure to do so predisposes to oncogenesis via ‘second-hit’ transforming events.

In RNA-seq gene expression experiments, we found that the RNA expression signatures of Lmo2-tg immature thymocytes and HSCs are very similar, consistent with the notion that Lmo2 overexpression ‘freezes’ cells in a stem-cell self-renewal state. To determine whether Ldb1 complexes are in fact required for ETP self renewal and to explore the genes regulated by these complexes, we conditionally deleted Ldb1 in Lmo2-tg mice. We found that Ldb1 is required for Lmo2-tg–induced thymocyte self renewal and T-ALL induction, indicating that Lmo2 overexpression promotes T-ALL by functioning as a subunit of Ldb1 complexes. Currently, we are addressing several key questions, including whether, as predicted, Ldb1, and by extension Ldb1 complexes, regulate expression of genes that control a self-renewal genetic program in ETPs and whether Ldb1 complexes are necessary for the transcriptional/developmental effects of Lmo2. We are also determining the subunit structure and binding sites of Ldb1 complexes expressed in Lmo2-tg thymocytes. We anticipate that our results will provide insights into the mechanisms controlling T-ALL oncogenesis in humans and may thus provide new therapeutic avenues for the treatment of this devastating pediatric disease.

Additional Funding

• NICHD Director's Award

Publications

1. Zhao B, Yoganathan K, Li L, Lee JY, Zúñiga-Pflücker JC, Love PE. Notch and the pre-TCR coordinate thymocyte proliferation by induction of the SCF subunits Fbxl1 and Fbxl12. Nat Immunol 2019;20:1381-1392.
2. Carmo AM, Love PE, Marshall AJ. Editorial: Inhibitory receptors and pathways of lymphocytes. Front Immunol 2020;11:1552.
3. Li L, Mitra A, Cui K, Zhao B, Choi S, Lee JY, Stamos DB, El-Khoury D, Warzecha C, Pfeifer K, Hardwick J, Zhao K, Venters B, Davé UP, Love PE. Ldb1 is required for Lmo2 oncogene-induced thymocyte self-renewal and T-cell acute lymphoblastic leukemia. Blood 2020;135:2252-2265.
4. Chen C, Sun MA, Warzecha C, Bachu M, Dey A, Wu T, Adams PD, Macfarlan T, Love P, Ozato K. HIRA, a DiGeorge syndrome candidate gene, confers proper chromatin accessibility on HSCs and supports all stages of hematopoiesis. Cell Rep 2020;30:2136-2149.
5. Blaize G, Daniels-Treffandier H, Aloulou M, Rouquié N, Yang C, Marcellin M, Gador M, Benamar M, Ducatez M, Song KD, Burlet-Schiltz O, Saoudi A, Love PE, Fazilleau N, Gonzalez de Peredo A, Lesourne R. CD5 signalosome coordinates antagonist TCR signals to control the generation of Treg cells induced by foreign antigens. Proc Natl Acad Sci USA 2020;117:12969-12979.
6. Matson CA, Choi S, Livak F, Zhao B, Mitra A, Love PE, Singh NJ. CD5 dynamically calibrates basal NF-kappaB signaling in T cells during thymic development and peripheral activation. Proc Natl Acad Sci USA 2020;117:14342-14353.

Collaborators

• Cheryl Arrowsmith, PhD, University of Toronto, Toronto, Canada
• Remy Bosselut, PhD, Laboratory of Immune Cell Biology, NCI, Bethesda, MD
• Richard J. Cornall, FMedSci, FRCP, University of Oxford, Oxford, United Kingdom
• Utpal P. Davé, MD, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN
• Lauren Ehrlich, PhD, The University of Texas at Austin, Austin, TX
• Christian Hinrichs, MD, Genitourinary Malignancies Branch, Center for Cancer Research, NCI, Bethesda, MD
• Aravind Iyer, PhD, Protein and Genome Evolution Research Group, NLM/NCBI, Bethesda, MD
• Park Jung-Hyun, PhD, Experimental Immunology Branch, Center for Cancer Research, NCI, Bethesda, MD
• Renaud Lesourne, PhD, INSERM, Toulouse, France
• Dorian McGavern, PhD, Viral Immunology and Intravital Imaging Section, NINDS, Bethesda, MD
• Keiko Ozato, PhD, Section on Molecular Genetics of Immunity, NICHD, Bethesda, MD
• Rita Perlingeiro, PhD, University of Minnesota Medical School, Minneapolis, MN
• Karl Pfeifer, PhD, Section on Epigenetics, NICHD, Bethesda, MD
• Alfred Singer, MD, Experimental Immunology Branch, Center for Cancer Research, NCI, Bethesda, MD
• Nevil Singh, PhD, University of Maryland School of Medicine, Baltimore, MD
• Naomi Taylor, MD, PhD, Pediatric Oncology Branch, Center for Cancer Research, NCI, Bethesda, MD
• Keji Zhao, PhD, Laboratory of Epigenome Biology, NHLBI, Bethesda, MD
• Juan Carlos Zúñiga-Pflücker, PhD, University of Toronto, Toronto, Canada

Contact

For more information, email lovep@mail.nih.gov or visit https://www.nichd.nih.gov/research/atNICHD/Investigators/love.

Top of Page